<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We report the outcome of 16 children with refractory <z:hpo ids='HP_0001903'>anaemia</z:hpo> with excess of blasts (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>; n = 4) and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> in transformation (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB-T</z:e>; n = 12) following induction therapy with <z:chebi fb="0" ids="4911">etoposide</z:chebi>, <z:chebi fb="0" ids="28680">cytarabine</z:chebi> and <z:chebi fb="0" ids="50729">mitoxantrone</z:chebi> (ECM) prior to haematopoietic stem cell transplantation (HSCT) </plain></SENT>
<SENT sid="1" pm="."><plain>The median observation period was 77 months (range 5-123) </plain></SENT>
<SENT sid="2" pm="."><plain>Complete remission rate was 81% following induction; no toxic <z:hpo ids='HP_0011420'>deaths</z:hpo> occurred </plain></SENT>
<SENT sid="3" pm="."><plain>Eight-year event-free survival and overall survival was 50% and 56%, respectively </plain></SENT>
<SENT sid="4" pm="."><plain>None of the three patients with a complex karyotype survived, suggesting karyotype is a crucial prognostic factor for survival </plain></SENT>
<SENT sid="5" pm="."><plain>This study indicates the safety and high remission rate of ECM and high survival rates after HSCT for paediatric <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB-T</z:e> </plain></SENT>
</text></document>